截至2025年8月8日收盘，瑞迈特股价报92.21元，较前一交易日上涨5.53元，涨幅6.38%。当日成交量为 30627手，成交金额达2.76亿元。 瑞迈特所属医疗器械板块，公司主营业务为医疗健康领域相关产品的研发、生产和销售。公司产品涵盖 多个医疗细分领域，在北京地区具有业务布局。 8月8日，瑞迈特发生一笔大宗交易，机构专用账户通过大宗交易方式买入20万股，成交金额1829.8万 元，成交价91.49元，较当日收盘价折价0.78%。该笔交易占当日成交金额的6.63%。 资金流向方面，8月8日主力资金净流入313.65万元，占流通市值的0.06%。近五个交易日主力资金累计 净流出1674.61万元，占流通市值的0.32%。 风险提示：股市有风险，投资需谨慎。 来源：金融界 ...

分行业来看，统计数据显示，剔除董秘已离任公司后，A股共有37家上市医疗设备公司，其聘任总体情 况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁的董秘是市场的中坚力量，占比共计达到44%；50岁以上的董秘占 比为25%；40岁及以下董秘群体占比为31%。其中，目前仍任职的最年轻的男上市公司董秘年龄36岁， 为康众医疗的尹晟；最年轻的女董秘年龄为32岁，为鱼跃医疗的王瑞洁。 专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 从薪酬变动幅度看，港通医疗的陈兴根2024年薪酬降幅最大，同比降幅达28.17%；瑞迈特的杜祎程薪 酬增幅最大，同比涨幅达87.43%。 责任编辑：公司观察 其中，年薪排行前五的董秘分别为迈瑞医疗的李文楣、联影医疗的TAO CAI、理邦仪器的祖幼冬、华大 智造的韦炜、鱼跃医疗的王瑞洁，五人年薪分别为738.76万元、165.11万元、16 ...

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. specializes in the manufacturing of medical devices and consumables in the respiratory health field [1] - The main products include various types of sleep breathing machines, masks, and monitoring devices [1] - The company holds a total of 633 domestic patents, including 107 invention patents and 390 utility model patents, as well as 202 international patents [1] Financial Performance - For Q1 2025, the company reported a revenue of 265 million yuan, representing a year-on-year increase of 38.11% [2] - The net profit for the same period was 71.93 million yuan, showing a year-on-year growth of 44.11% [2] - The gross profit margin stood at 49.57% [2] Market Position - As of August 6, the company's stock closed at 87.34 yuan, with a rolling price-to-earnings (PE) ratio of 44.11 times [1] - The average PE ratio in the medical device industry is 53.93 times, with a median of 37.81 times, placing Ruimait at the 83rd position in the industry ranking [1][2] - The total market capitalization of the company is 7.826 billion yuan [1]

北京瑞迈特医疗科技股份有限公司的主营业务是呼吸健康领域医疗设备与耗材产品制造。公司的主要产 品是单水平睡眠呼吸机、双水平睡眠呼吸机、双水平肺病呼吸机、P5系列单水平睡眠呼吸机、全脸面 罩、鼻面罩、鼻垫式面罩、睡眠呼吸初筛仪、多导睡眠呼吸监测仪、HT系列高流量湿化氧疗仪、H-80 系列高流量湿化氧疗仪、R系列双水平无创呼吸机。公司拥有633项国内专利，其中国内发明专利107 项、国内实用新型专利390项、国内外观设计专利136项；国际专利202项，其中包括美国专利39项、欧 洲专利30项、欧盟外观专利26项、英国专利46项、土耳其专利12项、日本专利21项、澳大利亚专利6 项、印度专利18项、沙特阿拉伯专利4项。 8月5日，瑞迈特今日收盘88.87元，上涨1.55%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到44.89倍，总市值79.63亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.24倍，行业中值37.92倍，瑞迈特排名 第83位。 资金流向方面，8月5日，瑞迈特主力资金净流入693.70万元，近5日总体呈流出状态，5日共流出2848.80 万元。 最新一期业绩显示，2 ...

Core Viewpoint - The stock price of Ruimait has increased by 1.71 yuan to 87.51 yuan, indicating positive market sentiment [1] Group 1: Stock Performance - The opening price was 85.36 yuan, with an intraday high of 87.65 yuan and a low of 84.85 yuan [1] - The trading volume reached 9,623 hands, with a total transaction amount of 0.83 billion yuan [1] - The company's total market capitalization is 7.841 billion yuan, while the circulating market capitalization is 4.946 billion yuan [1] Group 2: Fund Flow - On August 4, the net outflow of main funds was 6.028 million yuan, accounting for 0.12% of the circulating market capitalization [1] - Over the past five trading days, the cumulative net outflow reached 33.1115 million yuan, representing 0.67% of the circulating market capitalization [1]

证券代码：301367 证券简称：瑞迈特 公告编号：2025-045 北京瑞迈特医疗科技股份有限公司 关于持股5%以上股东及其一致行动人 减持股份触及1%整数倍的公告 公司持股5%以上股东珠海合晅投资中心（有限合伙）及其一致行动人上海 盛旻创业投资合伙企业（有限合伙）和南京合灏创业投资企业（有限合伙）保证 向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 2 | 京 | 其中：无限售条件股 | 35.8589 | 0.40 | 25.5189 | 0.28 | 合 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 份 | 灏 | 有限售条件股份 | | | | | | | | 0 | 0.00 | 0 | 0.00 | | | | | | | 持有股份 | 1,688.7790 | 18.85 | 1,604.7090 | 17.91 | | | | | | 合 | 其中：无限售条件股 | 1,688.7790 | 18.85 | 1,604.7090 | 17.91 | 计 | 份 | | | 有限售 ...

股东方面，截至2025年3月31日，瑞迈特股东户数9118户，较上次增加1481户，户均持股市值35.28万 元，户均持股数量2.76万股。 北京瑞迈特医疗科技股份有限公司的主营业务是呼吸健康领域医疗设备与耗材产品制造。公司的主要产 品是单水平睡眠呼吸机、双水平睡眠呼吸机、双水平肺病呼吸机、P5系列单水平睡眠呼吸机、全脸面 罩、鼻面罩、鼻垫式面罩、睡眠呼吸初筛仪、多导睡眠呼吸监测仪、HT系列高流量湿化氧疗仪、H-80 系列高流量湿化氧疗仪、R系列双水平无创呼吸机。公司拥有633项国内专利，其中国内发明专利107 项、国内实用新型专利390项、国内外观设计专利136项；国际专利202项，其中包括美国专利39项、欧 洲专利30项、欧盟外观专利26项、英国专利46项、土耳其专利12项、日本专利21项、澳大利亚专利6 项、印度专利18项、沙特阿拉伯专利4项。 7月30日，瑞迈特今日收盘86.19元，下跌1.14%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到43.53倍，总市值77.23亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.15倍，行业中值37.48倍，瑞迈特排名 第81 ...

Group 1 - The Beijing Future Science City Management Committee has developed a draft implementation plan for the "Artificial Intelligence + Pharmaceutical Health" industry in Changping District, focusing on brain-computer interface (BCI) innovation [1] - The plan emphasizes the development and application of BCI products, supporting research in key areas such as neural signal acquisition, decoding, control, and feedback [1] - The document encourages medical and health institutions in the region to adopt BCI products for clinical applications in treating neurological and mental disorders, as well as in smart rehabilitation and health monitoring [1] Group 2 - Open Source Securities highlights the significant potential of the downstream application market for brain-computer interfaces, which connect the brain with external devices for information exchange [2] - The BCI technology is expected to accelerate its implementation due to favorable policies and technological advancements, benefiting companies such as Rock Mountain Technology, Zhongke Information, and others [2] - The applications of BCI span across medical fields for disease warning, diagnosis, treatment, and functional enhancement, as well as in consumer and industrial sectors [2]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [15]. Core Insights - The company is expected to experience a rapid growth phase from 2025 to 2027, driven by the end of inventory cycles in overseas markets and the introduction of new products, including a noiseless cotton breathing machine [4][13]. - The domestic market is anticipated to benefit from a 30% national subsidy for home respiratory devices starting in 2025, which will enhance market penetration [4][13]. - The company's shift from a distribution model to direct sales is expected to improve factory prices and gross margins, further accelerating domestic growth [4][13]. Summary by Sections Company Overview - The company is a leading player in the home respiratory device market, with a comprehensive product line that includes single-level and dual-level breathing machines, medical breathing machines, sleep monitors, and high-flow humidified oxygen therapy devices [11][70]. Market Dynamics - The global home respiratory machine market reached approximately $2.71 billion in 2020, with the Chinese market size at about 1.23 billion yuan [9][60]. - The market for ventilatory masks was valued at $1.62 billion globally in 2020, with a compound annual growth rate (CAGR) of 9.7% from 2016 to 2020 [9][65]. Competitive Landscape - The global market for home non-invasive breathing machines is concentrated, with major players including ResMed, Philips, and the company itself, which holds the second-largest market share globally [10][69]. - In the breathing machine market, ResMed accounted for 40.3% of the global market share in 2020, while the company held a 26.6% share in China [10][69]. Product Performance - The company's new noiseless cotton breathing machine is expected to enhance its market share in overseas markets due to its effective noise reduction capabilities [12][76]. - The company has a strong focus on research and development, holding 633 domestic patents and 202 international patents, including 39 in the United States and 30 in Europe [76]. Financial Projections - The company is projected to achieve net profits of 255 million yuan, 332 million yuan, and 433 million yuan for the years 2025, 2026, and 2027, respectively, with corresponding price-to-earnings (PE) ratios of 31.30, 23.99, and 18.40 [13].

资金流向方面，7月28日，瑞迈特主力资金净流入106.41万元，近5日总体呈流出状态，5日共流出 4575.13万元。 北京瑞迈特医疗科技股份有限公司的主营业务是呼吸健康领域医疗设备与耗材产品制造。公司的主要产 品是单水平睡眠呼吸机、双水平睡眠呼吸机、双水平肺病呼吸机、P5系列单水平睡眠呼吸机、全脸面 罩、鼻面罩、鼻垫式面罩、睡眠呼吸初筛仪、多导睡眠呼吸监测仪、HT系列高流量湿化氧疗仪、H-80 系列高流量湿化氧疗仪、R系列双水平无创呼吸机。公司拥有633项国内专利，其中国内发明专利107 项、国内实用新型专利390项、国内外观设计专利136项；国际专利202项，其中包括美国专利39项、欧 洲专利30项、欧盟外观专利26项、英国专利46项、土耳其专利12项、日本专利21项、澳大利亚专利6 项、印度专利18项、沙特阿拉伯专利4项。 来源：金融界 最新一期业绩显示，2025年一季报，公司实现营业收入2.65亿元，同比38.11%；净利润7193.14万元， 同比44.11%，销售毛利率49.57%。 7月28日，瑞迈特今日收盘86.84元，下跌2.42%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达 ...